Inflazyme Pharmaceuticals (T.IZP) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: jackie who wrote (1341)	12/11/1999 7:21:00 PM
From: Sean Janzen	Read Replies (1) of 1501

Off Topic It is my understanding that typically there are restrictions on shares traded. It doesn't take a lot of buying to drive the price upwards. It's probably too premature to talk about anything similar happening with IZP. I was glad to see a biotech initiate a successful IPO. Maybe IZP can pull off a similar type financing in a few years after they get a few licensing deals under their belt. Here are a few more details on Tularik. After the offering, there will be about 41.3 million shares outstanding in the company, according to the filing. Subject 31221 Our product pipeline includes two cancer drug candidates in clinical testing, one cancer drug candidate for which an investigational new drug application, known as an IND, has been filed, one preclinical anti-CMV drug candidate and 14 early and advanced drug leads in our other programs. To date, we have: . identified numerous validated targets and other novel proteins that regulate the expression of disease-causing genes; . established more than 80 biochemical and cell-based assays for high throughput screening, known as HTS; . conducted more than 15 million drug screens using a library of more than 500,000 distinct compounds and natural products; . identified seven compounds that are early leads, seven compounds that are being optimized by chemists, one compound that is in preclinical development, one anti-cancer drug candidate for which we have filed an IND application and one anti-cancer drug candidate that is in phase 1 clinical trials; and . obtained a license for an anti-cancer drug candidate that we expect to enter phase 2 clinical trials in 2000. biz.yahoo.com We currently have corporate collaborations in six of our research programs

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next